The factor V Leiden (FV Leiden) and prothrombin G20210A mutations, are the most common established genetic risk factors for deep vein thrombosis (DVT). However, the relationship. between these mutations and arterial thrombotic syndromes (coronary heart disease, myocardial infarction, stroke) has not been established. Some studies have suggested a relationship between them, but other authors have considered it unlikely that these anomalies are a major risk factor for arterial thrombosis. From the clinical point of view, a question arises concerning the risk of repeated thrombosis in patients carrying one of these two mutations. The question is whether the recurrence is attributable to the mutations or to the presence of additional circumstantial risk factors. As the risk of repeated thrombosis varies considerably from one patient to another, decisions about long-term treatment require weighing the persistence of risk factors for vascular disease (venous and arterial), especially in selected cases such as young patients or patients with thrombosis of unusual localization.
Dahlback B., Carlsson M., Svensson PJFamilial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein. Proc Natl Acad Sci USA1993;90: 1004.
2.
Koster T., Rosendaal FR, De Ronde H, et al. Venous thrombosis due to poor anticoagulant response to activated protein C. Leiden Thrombophila Study. Lancet1993;342:1503.
3.
Bertina RM, Koeleman Bpl, Foister T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature1994;369:64.
4.
Poort SR, Rosendaal Fr, Reitsma PH, et al. A common genetic variation in the 3-un'translated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood1996;88:3698.
5.
Hillarp A., Zoller V., Svensson PJ, et al. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish out patients with verified deep venous thrombosis. Thromb Haemost1997;78:990.
6.
Lerover C. Mercier V, Oger E., et al. Prevalence of the 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost1998;80:49.
7.
Margaglione M., Brancaccio V., Giuliani N., et al. Increased risk for venous thrombosis in carriers of the prothrombin G-A 20210 gene variant . Ann Intern Med,1998;129:89.
8.
Souto JC, Coll I., Llobet D., et al. The prothrombin 20210 A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost1 998;80:366.
9.
Rosendaal Fr , Siscovick DS, Schwartz SM, et al. A common prothrombin variant (2021OG to A) increases the risk of myocardial infarction in young women. Blood1997;90:1747.
10.
Arruda VR, Annichino-Bizzachi JM, Goncalves MS, et al. Prevalence of the prothrombin gene variant (nt 20210 A) in venous thrombosis and arterial disease. Thromb Haemost1997;78:1426.
11.
Watzke HH, Schüttrumpf J., Graf S., et al. Increased prevalence of a polymorphism in the gene coding for human prothrombin in patients with coronary heart disease. Thromb Res1997;87:521.
12.
Arruda VR, Siquiera H., Chiaparini LC, et al. Prevalence of the prothrombin gene variant 20210G-A among patients with myocardial infarction. Cardiovasc Res1998;37:42,
13.
Doggen Cmj, Cats VM, Bertina RM, et al. Interaction of coagulation defects and cardiovascular risk factors. Increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210 A. Circulation1998;97:1037.
14.
Corral J., González-Conjeiro R., Lozano M., et al. The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. Br J Haematol1997;99:304.
15.
Ferraresi P. , Marchetti G., Legnani C. et al. The heterozygous 20210 G/A prothrombin genotype is associate with early venous thrombosis in inherited thrombophilias and is not increase in frequency in artery disease. ArterioselerThromb Vasc Biol1997;17:2418.
16.
Eikelboom, JW, Baker RJ, Parsons R., et al. No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease. Thromb Haemost1998;80:878-80.
17.
Croft SADaly ME, Steeds RP, et al. The prothrombin 20210 A allele and its association with myocardial infarction. Thromb Haemost1999:81:861.
18.
Halbmayer WM , Haushofer A., Shon R., et al. The prevalence of poor anticoagulant response to activated protein C (APC resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects . Blood Coagul Fibrinolysis1994;5:51.
19.
Lindblad B. , Svensson PJ, Dahlback B.Arterial and venous thromboembolism with,fatal outcome and resistance to activated protein C. Lancet1994;343:917.
20.
Simioni P., de Ronde H., Prandoni P., et al. Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke1995;26:885.
21.
Margaglione M., D'Andrea G., Giuliani N., et al. Inherited prothrombotic conditions and premature ischemic stroke. Sex difference in the association with factor V Leiden. Arterioscler Thromb Vasc Biol1999 ; 19:1751.
22.
Ridker PM, Hennekens CH, Lindpaihtner K., et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in appurently healthy men. N Engl J Med1995:332:912.
23.
Catto A., Carter A., Irelanb H., et al. Factor V Leiden gene mutation and thrombin generation in relation to the development of acute stroke. Arterioscler Thromb1995;15:783.
24.
Press RD, Liu XY, Beamer N., et al. Ischemic stroke in the elderly. ; Role of the common factor V mutation causing resistance to activated protein C. Stroke1996;27:44.
25.
Landi G., Cella E., Martinelli F., et al. Arg 506 GLN Factor V mutation and cerebral ischemia in the young . Stroke1996,27:1697.
26.
Sánchez J., Roman J., de la Torre MJ, et al. Low prevalence of factor V Leiden among patients with ischemic stroke. Haemostasis1997;27:9.
27.
Longstreth WT Jr, Rosendaal Fr , Siscovick DS, et al. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin variant (G20210A) . Stroke1998;29:577.
28.
Voetsh B., Damasceno BP, Camargo EC, et al. Inherited thrombo- ' philia as a risk factor for the development of ischemic stroke in young adults. Thromb Haemost2000:83:229.
29.
Simioni P., Prandoni P., Lensing A., et al. The risk of recurrent venous thromboembolism in patients with an Arg 506 Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med1997;336:399.
30.
Margaglione M., D'Andrea G., Colaizzo D., et al. Coexistence of factor V Leiden and factor II A 20210 mutations and recurrent venous thromboembolism . Thromb Haemost1999;82:1583.
31.
Rintelen C., Pabinger I., Knöbl P., et al. Probability of recurrence of thrombosis in patients with and without Factor V Leiden. Thromb Haemost1996 ;75:229.
32.
Eichinger S. , Pabinger I., Stümpflen A., et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost1997;77:624.
33.
Lindmarker P. , Schulman S., Sten-Linder M., et al. Dural trial study group. The risk of recurrent venous thromboembolism in carriers and non carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost1999,81:684.
34.
Eichinger S. , Minar E., Hirschl M., et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost1999;81:14.
35.
De Stefano V, Martinelli I., Mannucci PM, et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med1999;341:801.
36.
Piemontino V., Guiotto G., Rugiada F., et al. Abnormally high frequency of inherited pro-thrombotic conditions in subjects with recurrence of venous thrombosis . Thromb Haemost1999 ;82:1359.
37.
Kearon C., Gent M., Hirsh J., et al. Comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med1999:340:901.
